Siani A, Strazzullo P, Russo L, Guglielmi S, Iacoviello L, Ferrara L A, Mancini M
Br Med J (Clin Res Ed). 1987 Jun 6;294(6585):1453-6. doi: 10.1136/bmj.294.6585.1453.
A 15 week randomised double blind placebo controlled trial of oral potassium supplements (48 mmol daily) was conducted in 37 patients who had mildly increased blood pressure and a normal dietary intake of sodium. After a two month run in and a one week baseline period the patients were randomly assigned to receive either potassium supplements (n = 18) or placebo (n = 19). By the third week of treatment blood pressure in the actively treated group had decreased significantly compared with that in the placebo group, though the decrease reached its maximum after 15 weeks. Urinary potassium excretion increased significantly in the group who received potassium supplements, but no significant changes were found in plasma sodium and potassium concentrations or in urinary sodium excretion. In a subgroup of 13 patients who underwent a further nine weeks of treatment with oral potassium supplements at half of the previous dose (24 mmol daily) their blood pressure, at the end of this second study period, was still significantly lower compared with their baseline value but not with that of the placebo group. These results show that moderate oral potassium supplements are associated with a long term reduction in blood pressure in patients who have mild hypertension.
对37名血压轻度升高且钠摄入正常的患者进行了一项为期15周的随机双盲安慰剂对照试验,试验内容为口服钾补充剂(每日48毫摩尔)。在经过两个月的磨合期和一周的基线期后,患者被随机分配接受钾补充剂(n = 18)或安慰剂(n = 19)。到治疗第三周时,积极治疗组的血压与安慰剂组相比显著下降,不过这种下降在15周后达到最大值。接受钾补充剂的组尿钾排泄显著增加,但血浆钠和钾浓度以及尿钠排泄均未发现显著变化。在一个由13名患者组成的亚组中,他们以先前剂量的一半(每日24毫摩尔)继续口服钾补充剂治疗9周,在第二个研究期结束时,他们的血压与基线值相比仍显著降低,但与安慰剂组相比则无显著差异。这些结果表明,中度口服钾补充剂与轻度高血压患者血压的长期降低有关。